无干扰素疗法在我国慢性丙型肝炎治疗中的应用  

Application of interferon-free treatment regimen in treatment of chronic hepatitis C in China

作　　者：聂红明[1] 陈建杰[1] 汪蓉 申宏[1] 

机构地区：[1]上海中医药大学附属曙光医院,上海200021 [2]上海浦东新区中医医院,上海200021

出　　处：《临床肝胆病杂志》2015年第5期796-799,共4页Journal of Clinical Hepatology

基　　金：十二五国家科技重大专项(2012ZX10005004-003);上海市卫生局新优青培养计划(XYQ2011066);上海市科委青年科技启明星计划(11QA1406700);国家自然科学基金(81373618);国家自然科学基金(81001492);上海高校创新团队建设项目(第一期);国家中医药管理局重点学科(中医传染病学)建设项目;上海重中之重临床医学中心(中医肝病)建设项目

摘　　要：随着新型口服的直接抗病毒药物(DAA)的上市,丙型肝炎迎来了无干扰素(IFN)治疗时代,其Ⅱ、Ⅲ期临床试验疗效接近治愈,似乎宣示人类将要迎来告别丙型肝炎的时代。我国作为丙型肝炎高发地区,聚乙二醇干扰素(PEG-IFN)联合利巴韦林(RBV)的标准治疗方案是否也要被即将来临的无IFN时代所完全替代不得而知。在此背景下,根据我国丙型肝炎的治疗历史和现状,尤其是PEG-IFN联合RBV的标准治疗方案在我国丙型肝炎治疗中的优势,结合国内外DAA研究进展,分析了DAA可能存在的问题和我国现阶段丙型肝炎治疗的主体方向。可以预见,PEG-IFN联合RBV的治疗方案仍将是现阶段我国慢性丙型肝炎患者治疗的主导方案。With the release of new oral direct -acting antiviral agents （DAAs）,the interferon （IFN）-free treatment for hepatitis C comes out,and the clinical efficacy in phase II and III clinical trials is close to cure,which seems to announce the end of the era of hepatitis C.In China,an area of high incidence of hepatitis C,pegylated interferon （PEG -IFN）combined with ribavirin （RBV）（the standard of care） has been the dominant treatment regimen for hepatitis C,and it is uncertain whether it will be completely replaced by interferon -free treat-ment regimen.In this background,this paper analyzes the possible problems of DAAs and the main treatment direction of hepatitis C in Chi-na at the present stage based on the history and present situation of treatment of hepatitis C,especially the advantage of PEG -IFN combined with RBV in the treatment of hepatitis C in China,and the research advances in DAAs at home and abroad.It is found that PEG -IFN com-bined with RBV will remain the dominant treatment regimen for chronic hepatitis C at the present stage.

关 键 词：肝炎 丙型 慢性 抗病毒药 干扰素类 综述 

分 类 号：R512.63[医药卫生—内科学]